Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence

NCT02778282 · View on ClinicalTrials.gov ↗

Study Summary

The goal of the MySafeRx study is to evaluate the feasibility, acceptability, and usability of a novel platform that integrates text messaging reminders, secure electronic pill organizers, and daily remote brief motivational recovery support visits with a standardized protocol for supervised self- administration of buprenorphine via videoconferencing.

Conditions Studied

Interventions

  • OTHER MySafeRx™

Study Locations (3)

Vermont

  • Hawthorn Recovery Center — Bennington
  • Mount Anthony Primary Care — Bennington

Massachusetts

  • Cambridge Health Alliance Outpatient Addiction Services — Somerville

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2017-03-24
Est. Completion 2021-08-31
Phase NA

Sponsor

Dartmouth-Hitchcock Medical Center

396 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02778282

The ClinicalTrials.gov registry entry for NCT02778282 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 396 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention — of which MySafeRx™ is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02778282 reports 3 study locations spanning 2 distinct geographic areas — top geographies include Vermont, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02778282 about?

NCT02778282 is a clinical study titled "MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence". The goal of the MySafeRx study is to evaluate the feasibility, acceptability, and usability of a novel platform that integrates text messaging reminders, secure electronic pill organizers, and daily remote brief motivational recovery support visits with a standardized protocol for supervised self- a...

What is the current status of trial NCT02778282?

This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2017-03-24. Estimated completion is 2021-08-31.

What conditions does trial NCT02778282 study?

This clinical trial studies the following conditions: Opioid Use Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02778282?

The interventions under investigation include: MySafeRx™ (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02778282?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02778282 being conducted?

This trial has 3 study locations across Massachusetts, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial